nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CHRM5—Tiotropium—chronic obstructive pulmonary disease	0.226	0.3	CbGbCtD
Solifenacin—CHRM3—Tiotropium—chronic obstructive pulmonary disease	0.145	0.192	CbGbCtD
Solifenacin—CHRM1—Tiotropium—chronic obstructive pulmonary disease	0.126	0.167	CbGbCtD
Solifenacin—CHRM2—Tiotropium—chronic obstructive pulmonary disease	0.116	0.154	CbGbCtD
Solifenacin—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0398	0.0528	CbGbCtD
Solifenacin—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0269	0.0357	CbGbCtD
Solifenacin—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0257	0.034	CbGbCtD
Solifenacin—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0229	0.0303	CbGbCtD
Solifenacin—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0134	0.0178	CbGbCtD
Solifenacin—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0127	0.0168	CbGbCtD
Solifenacin—Benazepril—ACE—chronic obstructive pulmonary disease	0.00233	1	CrCbGaD
Solifenacin—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.000616	0.00289	CcSEcCtD
Solifenacin—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.000615	0.00288	CcSEcCtD
Solifenacin—Oedema peripheral—Formoterol—chronic obstructive pulmonary disease	0.000615	0.00288	CcSEcCtD
Solifenacin—Oedema peripheral—Arformoterol—chronic obstructive pulmonary disease	0.000615	0.00288	CcSEcCtD
Solifenacin—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.000613	0.00287	CcSEcCtD
Solifenacin—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.000613	0.00287	CcSEcCtD
Solifenacin—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.000612	0.00287	CcSEcCtD
Solifenacin—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.000612	0.00287	CcSEcCtD
Solifenacin—Hallucination—Montelukast—chronic obstructive pulmonary disease	0.000608	0.00285	CcSEcCtD
Solifenacin—Pharyngitis—Montelukast—chronic obstructive pulmonary disease	0.000607	0.00284	CcSEcCtD
Solifenacin—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.000604	0.00283	CcSEcCtD
Solifenacin—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.000601	0.00281	CcSEcCtD
Solifenacin—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.000599	0.00281	CcSEcCtD
Solifenacin—Palpitations—Tiotropium—chronic obstructive pulmonary disease	0.000595	0.00279	CcSEcCtD
Solifenacin—Cough—Tiotropium—chronic obstructive pulmonary disease	0.000587	0.00275	CcSEcCtD
Solifenacin—Pharyngitis—Salbutamol—chronic obstructive pulmonary disease	0.000585	0.00274	CcSEcCtD
Solifenacin—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.000582	0.00273	CcSEcCtD
Solifenacin—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.000582	0.00273	CcSEcCtD
Solifenacin—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.000581	0.00272	CcSEcCtD
Solifenacin—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000579	0.00271	CcSEcCtD
Solifenacin—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000579	0.00271	CcSEcCtD
Solifenacin—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.000579	0.00271	CcSEcCtD
Solifenacin—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000579	0.00271	CcSEcCtD
Solifenacin—Erythema multiforme—Montelukast—chronic obstructive pulmonary disease	0.000578	0.00271	CcSEcCtD
Solifenacin—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000578	0.00271	CcSEcCtD
Solifenacin—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.000578	0.00271	CcSEcCtD
Solifenacin—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000571	0.00268	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000569	0.00267	CcSEcCtD
Solifenacin—Delirium—Prednisone—chronic obstructive pulmonary disease	0.000569	0.00266	CcSEcCtD
Solifenacin—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.000568	0.00266	CcSEcCtD
Solifenacin—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.000567	0.00266	CcSEcCtD
Solifenacin—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000564	0.00264	CcSEcCtD
Solifenacin—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.000564	0.00264	CcSEcCtD
Solifenacin—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000562	0.00263	CcSEcCtD
Solifenacin—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000562	0.00263	CcSEcCtD
Solifenacin—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.00056	0.00263	CcSEcCtD
Solifenacin—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000555	0.0026	CcSEcCtD
Solifenacin—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.000552	0.00259	CcSEcCtD
Solifenacin—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000551	0.00258	CcSEcCtD
Solifenacin—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000551	0.00258	CcSEcCtD
Solifenacin—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00055	0.00258	CcSEcCtD
Solifenacin—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000547	0.00256	CcSEcCtD
Solifenacin—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000547	0.00256	CcSEcCtD
Solifenacin—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.000547	0.00256	CcSEcCtD
Solifenacin—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.000547	0.00256	CcSEcCtD
Solifenacin—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000546	0.00256	CcSEcCtD
Solifenacin—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000543	0.00254	CcSEcCtD
Solifenacin—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000543	0.00254	CcSEcCtD
Solifenacin—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000539	0.00252	CcSEcCtD
Solifenacin—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000536	0.00251	CcSEcCtD
Solifenacin—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000535	0.00251	CcSEcCtD
Solifenacin—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.000535	0.0025	CcSEcCtD
Solifenacin—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000534	0.0025	CcSEcCtD
Solifenacin—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000532	0.00249	CcSEcCtD
Solifenacin—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.000532	0.00249	CcSEcCtD
Solifenacin—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.000532	0.00249	CcSEcCtD
Solifenacin—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000531	0.00249	CcSEcCtD
Solifenacin—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000519	0.00243	CcSEcCtD
Solifenacin—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000516	0.00242	CcSEcCtD
Solifenacin—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000513	0.0024	CcSEcCtD
Solifenacin—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000513	0.0024	CcSEcCtD
Solifenacin—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000506	0.00237	CcSEcCtD
Solifenacin—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000502	0.00235	CcSEcCtD
Solifenacin—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000496	0.00233	CcSEcCtD
Solifenacin—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000496	0.00233	CcSEcCtD
Solifenacin—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000486	0.00228	CcSEcCtD
Solifenacin—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000484	0.00227	CcSEcCtD
Solifenacin—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.00048	0.00225	CcSEcCtD
Solifenacin—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.00048	0.00225	CcSEcCtD
Solifenacin—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000476	0.00223	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000474	0.00222	CcSEcCtD
Solifenacin—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000474	0.00222	CcSEcCtD
Solifenacin—Cough—Formoterol—chronic obstructive pulmonary disease	0.000474	0.00222	CcSEcCtD
Solifenacin—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.00047	0.0022	CcSEcCtD
Solifenacin—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00047	0.0022	CcSEcCtD
Solifenacin—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000469	0.0022	CcSEcCtD
Solifenacin—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000469	0.0022	CcSEcCtD
Solifenacin—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000469	0.0022	CcSEcCtD
Solifenacin—Cough—Montelukast—chronic obstructive pulmonary disease	0.000464	0.00218	CcSEcCtD
Solifenacin—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000463	0.00217	CcSEcCtD
Solifenacin—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00046	0.00216	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000459	0.00215	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000459	0.00215	CcSEcCtD
Solifenacin—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000453	0.00212	CcSEcCtD
Solifenacin—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000452	0.00212	CcSEcCtD
Solifenacin—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000452	0.00212	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00045	0.00211	CcSEcCtD
Solifenacin—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000449	0.0021	CcSEcCtD
Solifenacin—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000448	0.0021	CcSEcCtD
Solifenacin—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000448	0.0021	CcSEcCtD
Solifenacin—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000443	0.00208	CcSEcCtD
Solifenacin—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000443	0.00208	CcSEcCtD
Solifenacin—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000443	0.00207	CcSEcCtD
Solifenacin—Infection—Arformoterol—chronic obstructive pulmonary disease	0.00044	0.00206	CcSEcCtD
Solifenacin—Infection—Formoterol—chronic obstructive pulmonary disease	0.00044	0.00206	CcSEcCtD
Solifenacin—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000436	0.00204	CcSEcCtD
Solifenacin—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000435	0.00204	CcSEcCtD
Solifenacin—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000435	0.00204	CcSEcCtD
Solifenacin—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000434	0.00203	CcSEcCtD
Solifenacin—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000434	0.00203	CcSEcCtD
Solifenacin—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000433	0.00203	CcSEcCtD
Solifenacin—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000433	0.00203	CcSEcCtD
Solifenacin—Infection—Montelukast—chronic obstructive pulmonary disease	0.000431	0.00202	CcSEcCtD
Solifenacin—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000431	0.00202	CcSEcCtD
Solifenacin—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000431	0.00202	CcSEcCtD
Solifenacin—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000431	0.00202	CcSEcCtD
Solifenacin—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000429	0.00201	CcSEcCtD
Solifenacin—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000427	0.002	CcSEcCtD
Solifenacin—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000426	0.002	CcSEcCtD
Solifenacin—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000422	0.00198	CcSEcCtD
Solifenacin—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000419	0.00196	CcSEcCtD
Solifenacin—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000416	0.00195	CcSEcCtD
Solifenacin—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000412	0.00193	CcSEcCtD
Solifenacin—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00041	0.00192	CcSEcCtD
Solifenacin—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000409	0.00191	CcSEcCtD
Solifenacin—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000407	0.0019	CcSEcCtD
Solifenacin—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000405	0.0019	CcSEcCtD
Solifenacin—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000394	0.00185	CcSEcCtD
Solifenacin—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000394	0.00185	CcSEcCtD
Solifenacin—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.00039	0.00183	CcSEcCtD
Solifenacin—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.00039	0.00183	CcSEcCtD
Solifenacin—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000389	0.00182	CcSEcCtD
Solifenacin—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000386	0.00181	CcSEcCtD
Solifenacin—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000385	0.0018	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000383	0.00179	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000383	0.00179	CcSEcCtD
Solifenacin—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000382	0.00179	CcSEcCtD
Solifenacin—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000382	0.00179	CcSEcCtD
Solifenacin—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000382	0.00179	CcSEcCtD
Solifenacin—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000379	0.00178	CcSEcCtD
Solifenacin—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000379	0.00178	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000375	0.00176	CcSEcCtD
Solifenacin—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000374	0.00175	CcSEcCtD
Solifenacin—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000372	0.00174	CcSEcCtD
Solifenacin—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00037	0.00174	CcSEcCtD
Solifenacin—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000368	0.00173	CcSEcCtD
Solifenacin—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000367	0.00172	CcSEcCtD
Solifenacin—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000367	0.00172	CcSEcCtD
Solifenacin—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000365	0.00171	CcSEcCtD
Solifenacin—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000365	0.00171	CcSEcCtD
Solifenacin—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000365	0.00171	CcSEcCtD
Solifenacin—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000364	0.0017	CcSEcCtD
Solifenacin—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000363	0.0017	CcSEcCtD
Solifenacin—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000362	0.0017	CcSEcCtD
Solifenacin—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000362	0.0017	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000361	0.00169	CcSEcCtD
Solifenacin—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000361	0.00169	CcSEcCtD
Solifenacin—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000358	0.00168	CcSEcCtD
Solifenacin—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000355	0.00166	CcSEcCtD
Solifenacin—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000352	0.00165	CcSEcCtD
Solifenacin—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000352	0.00165	CcSEcCtD
Solifenacin—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.00035	0.00164	CcSEcCtD
Solifenacin—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.00035	0.00164	CcSEcCtD
Solifenacin—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000349	0.00164	CcSEcCtD
Solifenacin—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000346	0.00162	CcSEcCtD
Solifenacin—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000346	0.00162	CcSEcCtD
Solifenacin—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000346	0.00162	CcSEcCtD
Solifenacin—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000345	0.00162	CcSEcCtD
Solifenacin—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000345	0.00162	CcSEcCtD
Solifenacin—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000344	0.00161	CcSEcCtD
Solifenacin—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000343	0.00161	CcSEcCtD
Solifenacin—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000342	0.0016	CcSEcCtD
Solifenacin—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000333	0.00156	CcSEcCtD
Solifenacin—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000331	0.00155	CcSEcCtD
Solifenacin—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000327	0.00153	CcSEcCtD
Solifenacin—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000327	0.00153	CcSEcCtD
Solifenacin—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000326	0.00153	CcSEcCtD
Solifenacin—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000325	0.00152	CcSEcCtD
Solifenacin—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.00032	0.0015	CcSEcCtD
Solifenacin—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000318	0.00149	CcSEcCtD
Solifenacin—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000318	0.00149	CcSEcCtD
Solifenacin—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000314	0.00147	CcSEcCtD
Solifenacin—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000314	0.00147	CcSEcCtD
Solifenacin—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000313	0.00147	CcSEcCtD
Solifenacin—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000312	0.00146	CcSEcCtD
Solifenacin—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000308	0.00144	CcSEcCtD
Solifenacin—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000307	0.00144	CcSEcCtD
Solifenacin—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.0003	0.00141	CcSEcCtD
Solifenacin—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000296	0.00139	CcSEcCtD
Solifenacin—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000293	0.00137	CcSEcCtD
Solifenacin—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000293	0.00137	CcSEcCtD
Solifenacin—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000287	0.00135	CcSEcCtD
Solifenacin—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000282	0.00132	CcSEcCtD
Solifenacin—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000282	0.00132	CcSEcCtD
Solifenacin—Rash—Formoterol—chronic obstructive pulmonary disease	0.00028	0.00131	CcSEcCtD
Solifenacin—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00028	0.00131	CcSEcCtD
Solifenacin—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000279	0.00131	CcSEcCtD
Solifenacin—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000279	0.00131	CcSEcCtD
Solifenacin—Headache—Formoterol—chronic obstructive pulmonary disease	0.000278	0.0013	CcSEcCtD
Solifenacin—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000278	0.0013	CcSEcCtD
Solifenacin—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000277	0.0013	CcSEcCtD
Solifenacin—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000277	0.0013	CcSEcCtD
Solifenacin—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000276	0.00129	CcSEcCtD
Solifenacin—Rash—Montelukast—chronic obstructive pulmonary disease	0.000274	0.00128	CcSEcCtD
Solifenacin—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000274	0.00128	CcSEcCtD
Solifenacin—Depression—Prednisone—chronic obstructive pulmonary disease	0.000273	0.00128	CcSEcCtD
Solifenacin—Headache—Montelukast—chronic obstructive pulmonary disease	0.000272	0.00127	CcSEcCtD
Solifenacin—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000269	0.00126	CcSEcCtD
Solifenacin—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000266	0.00125	CcSEcCtD
Solifenacin—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000264	0.00124	CcSEcCtD
Solifenacin—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000264	0.00124	CcSEcCtD
Solifenacin—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000263	0.00123	CcSEcCtD
Solifenacin—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000263	0.00123	CcSEcCtD
Solifenacin—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000262	0.00123	CcSEcCtD
Solifenacin—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000258	0.00121	CcSEcCtD
Solifenacin—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000254	0.00119	CcSEcCtD
Solifenacin—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000249	0.00116	CcSEcCtD
Solifenacin—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000244	0.00114	CcSEcCtD
Solifenacin—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000241	0.00113	CcSEcCtD
Solifenacin—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.00024	0.00112	CcSEcCtD
Solifenacin—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000234	0.0011	CcSEcCtD
Solifenacin—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000229	0.00108	CcSEcCtD
Solifenacin—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000223	0.00104	CcSEcCtD
Solifenacin—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000222	0.00104	CcSEcCtD
Solifenacin—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000215	0.00101	CcSEcCtD
Solifenacin—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000214	0.001	CcSEcCtD
Solifenacin—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000201	0.000944	CcSEcCtD
Solifenacin—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000198	0.000927	CcSEcCtD
Solifenacin—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000195	0.000915	CcSEcCtD
Solifenacin—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000191	0.000894	CcSEcCtD
Solifenacin—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000185	0.000865	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000181	0.000847	CcSEcCtD
Solifenacin—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000177	0.000829	CcSEcCtD
Solifenacin—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000174	0.000817	CcSEcCtD
Solifenacin—Infection—Prednisone—chronic obstructive pulmonary disease	0.000173	0.000812	CcSEcCtD
Solifenacin—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000171	0.000802	CcSEcCtD
Solifenacin—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.00017	0.000798	CcSEcCtD
Solifenacin—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000169	0.000794	CcSEcCtD
Solifenacin—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000159	0.000744	CcSEcCtD
Solifenacin—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000154	0.00072	CcSEcCtD
Solifenacin—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000152	0.000711	CcSEcCtD
Solifenacin—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000151	0.000709	CcSEcCtD
Solifenacin—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000151	0.000709	CcSEcCtD
Solifenacin—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.00015	0.000705	CcSEcCtD
Solifenacin—Headache—Prednisolone—chronic obstructive pulmonary disease	0.00015	0.000705	CcSEcCtD
Solifenacin—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000149	0.000699	CcSEcCtD
Solifenacin—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000144	0.000674	CcSEcCtD
Solifenacin—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000668	CcSEcCtD
Solifenacin—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000143	0.000668	CcSEcCtD
Solifenacin—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000139	0.000649	CcSEcCtD
Solifenacin—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000138	0.000646	CcSEcCtD
Solifenacin—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000602	CcSEcCtD
Solifenacin—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000125	0.000586	CcSEcCtD
Solifenacin—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000578	CcSEcCtD
Solifenacin—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000541	CcSEcCtD
Solifenacin—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000111	0.00052	CcSEcCtD
Solifenacin—Rash—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000515	CcSEcCtD
Solifenacin—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000515	CcSEcCtD
Solifenacin—Headache—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000512	CcSEcCtD
Solifenacin—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000486	CcSEcCtD
Solifenacin—CHRM5—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	5.8e-05	0.00195	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	5.76e-05	0.00193	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	5.75e-05	0.00193	CbGpPWpGaD
Solifenacin—CHRM4—Regulation of Actin Cytoskeleton—EGFR—chronic obstructive pulmonary disease	5.65e-05	0.0019	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.5e-05	0.00185	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	5.43e-05	0.00182	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	5.42e-05	0.00182	CbGpPWpGaD
Solifenacin—CHRM5—Regulation of Actin Cytoskeleton—EGFR—chronic obstructive pulmonary disease	5.41e-05	0.00181	CbGpPWpGaD
Solifenacin—CHRM4—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	5.36e-05	0.0018	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	5.36e-05	0.0018	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	5.32e-05	0.00179	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.32e-05	0.00179	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	5.3e-05	0.00178	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.27e-05	0.00177	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	5.26e-05	0.00176	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	5.25e-05	0.00176	CbGpPWpGaD
Solifenacin—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	5.2e-05	0.00174	CbGpPWpGaD
Solifenacin—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5.14e-05	0.00172	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.09e-05	0.00171	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	5.07e-05	0.0017	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	5.05e-05	0.0017	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	5.03e-05	0.00169	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	5e-05	0.00168	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	4.96e-05	0.00166	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	4.84e-05	0.00162	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	4.75e-05	0.0016	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	4.66e-05	0.00156	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	4.64e-05	0.00156	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	4.6e-05	0.00154	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	4.6e-05	0.00154	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	4.59e-05	0.00154	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	4.54e-05	0.00152	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	4.53e-05	0.00152	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	4.52e-05	0.00152	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	4.48e-05	0.0015	CbGpPWpGaD
Solifenacin—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.32e-05	0.00145	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.28e-05	0.00144	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.27e-05	0.00143	CbGpPWpGaD
Solifenacin—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.26e-05	0.00143	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—GC—chronic obstructive pulmonary disease	4.16e-05	0.0014	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.09e-05	0.00137	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.08e-05	0.00137	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.07e-05	0.00137	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	4.05e-05	0.00136	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	4.04e-05	0.00136	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.03e-05	0.00135	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.03e-05	0.00135	CbGpPWpGaD
Solifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	4.03e-05	0.00135	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	4.03e-05	0.00135	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	4e-05	0.00134	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.87e-05	0.0013	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.86e-05	0.0013	CbGpPWpGaD
Solifenacin—CHRM1—Regulation of Actin Cytoskeleton—EGFR—chronic obstructive pulmonary disease	3.81e-05	0.00128	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.8e-05	0.00128	CbGpPWpGaD
Solifenacin—CHRM3—Regulation of Actin Cytoskeleton—EGFR—chronic obstructive pulmonary disease	3.79e-05	0.00127	CbGpPWpGaD
Solifenacin—CHRM2—Regulation of Actin Cytoskeleton—EGFR—chronic obstructive pulmonary disease	3.76e-05	0.00126	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	3.71e-05	0.00125	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	3.7e-05	0.00124	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	3.66e-05	0.00123	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.64e-05	0.00122	CbGpPWpGaD
Solifenacin—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.6e-05	0.00121	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.59e-05	0.0012	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.58e-05	0.0012	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	3.57e-05	0.0012	CbGpPWpGaD
Solifenacin—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.55e-05	0.00119	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.55e-05	0.00119	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.54e-05	0.00119	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.53e-05	0.00119	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.5e-05	0.00117	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.45e-05	0.00116	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	3.45e-05	0.00116	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.4e-05	0.00114	CbGpPWpGaD
Solifenacin—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.31e-05	0.00111	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.31e-05	0.00111	CbGpPWpGaD
Solifenacin—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.26e-05	0.0011	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.25e-05	0.00109	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.25e-05	0.00109	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.25e-05	0.00109	CbGpPWpGaD
Solifenacin—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.14e-05	0.00105	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.11e-05	0.00104	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.11e-05	0.00104	CbGpPWpGaD
Solifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	3.1e-05	0.00104	CbGpPWpGaD
Solifenacin—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.09e-05	0.00104	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.08e-05	0.00104	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.97e-05	0.000997	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.95e-05	0.000991	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.88e-05	0.000965	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.87e-05	0.000962	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.85e-05	0.000955	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.84e-05	0.000953	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	2.84e-05	0.000953	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	2.83e-05	0.00095	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	2.78e-05	0.000934	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.72e-05	0.000913	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.71e-05	0.00091	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.7e-05	0.000906	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.68e-05	0.000901	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.58e-05	0.000867	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.56e-05	0.00086	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.55e-05	0.000857	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.53e-05	0.000849	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.52e-05	0.000847	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	2.52e-05	0.000844	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.38e-05	0.000798	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.33e-05	0.000781	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.32e-05	0.000779	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.3e-05	0.000773	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.3e-05	0.000771	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.29e-05	0.000769	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.28e-05	0.000766	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.28e-05	0.000764	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.27e-05	0.000763	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.26e-05	0.000759	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—GCLC—chronic obstructive pulmonary disease	2.25e-05	0.000754	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.21e-05	0.000742	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.19e-05	0.000736	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.19e-05	0.000735	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.18e-05	0.000733	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.18e-05	0.000733	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	2.18e-05	0.000732	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	2.17e-05	0.00073	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.16e-05	0.000726	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.16e-05	0.000726	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.12e-05	0.00071	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.08e-05	0.000698	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.07e-05	0.000696	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.05e-05	0.000689	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CTGF—chronic obstructive pulmonary disease	2.05e-05	0.000688	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.04e-05	0.000684	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2e-05	0.000672	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2e-05	0.00067	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.98e-05	0.000664	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.95e-05	0.000655	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.89e-05	0.000634	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.84e-05	0.000616	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.82e-05	0.000612	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.82e-05	0.000611	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.81e-05	0.000609	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.8e-05	0.000603	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.76e-05	0.00059	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.74e-05	0.000586	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.67e-05	0.000561	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.67e-05	0.00056	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.66e-05	0.000556	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.63e-05	0.000546	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.6e-05	0.000538	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.6e-05	0.000536	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.6e-05	0.000536	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.59e-05	0.000535	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.59e-05	0.000532	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.58e-05	0.000531	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.58e-05	0.000529	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.55e-05	0.000521	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.53e-05	0.000512	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.51e-05	0.000508	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.49e-05	0.0005	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.48e-05	0.000498	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.48e-05	0.000497	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.47e-05	0.000494	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.45e-05	0.000486	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.42e-05	0.000476	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.37e-05	0.000461	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.37e-05	0.000461	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.37e-05	0.00046	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.36e-05	0.000456	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.24e-05	0.000415	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.23e-05	0.000414	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.23e-05	0.000412	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.22e-05	0.000411	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.22e-05	0.00041	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.22e-05	0.000409	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.21e-05	0.000407	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.17e-05	0.000392	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.16e-05	0.00039	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.12e-05	0.000377	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.12e-05	0.000376	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.12e-05	0.000375	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.11e-05	0.000374	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.11e-05	0.000374	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.11e-05	0.000373	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.11e-05	0.000372	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.1e-05	0.00037	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.07e-05	0.000361	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.07e-05	0.00036	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.06e-05	0.000357	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.06e-05	0.000356	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.99e-06	0.000335	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.96e-06	0.000334	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.86e-06	0.000331	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.85e-06	0.000331	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.43e-06	0.000317	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.36e-06	0.000314	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ALB—chronic obstructive pulmonary disease	9.33e-06	0.000313	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.97e-06	0.000301	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—NOS3—chronic obstructive pulmonary disease	8.92e-06	0.0003	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.91e-06	0.000299	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.88e-06	0.000298	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	8.78e-06	0.000295	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.53e-06	0.000286	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	8.21e-06	0.000276	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	8.19e-06	0.000275	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	8.11e-06	0.000272	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	8.01e-06	0.000269	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8e-06	0.000268	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.84e-06	0.000263	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.82e-06	0.000262	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.74e-06	0.00026	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.66e-06	0.000257	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.49e-06	0.000251	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.46e-06	0.00025	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.39e-06	0.000248	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.38e-06	0.000248	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.34e-06	0.000246	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.2e-06	0.000242	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.03e-06	0.000236	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.89e-06	0.000231	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.64e-06	0.000223	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.62e-06	0.000222	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.55e-06	0.00022	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.31e-06	0.000212	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.29e-06	0.000211	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.23e-06	0.000209	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.16e-06	0.000207	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.07e-06	0.000204	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.04e-06	0.000203	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.01e-06	0.000202	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.99e-06	0.000201	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.93e-06	0.000199	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.79e-06	0.000194	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.66e-06	0.00019	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.53e-06	0.000186	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.39e-06	0.000181	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.38e-06	0.00018	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.36e-06	0.00018	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.32e-06	0.000179	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.3e-06	0.000178	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.95e-06	0.000166	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.93e-06	0.000166	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.89e-06	0.000164	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.85e-06	0.000163	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.84e-06	0.000162	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.79e-06	0.000161	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.07e-06	0.000137	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.06e-06	0.000136	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.02e-06	0.000135	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.73e-06	0.000125	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.72e-06	0.000125	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.68e-06	0.000124	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.65e-06	0.000122	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	3.49e-06	0.000117	CbGpPWpGaD
